Today The Amicus Therapeutics, Inc. (FOLD) Upgraded to Outperform by Robert W. Baird

Today The Amicus Therapeutics, Inc. (FOLD) Upgraded to Outperform by Robert W. Baird

Robert W. Baird upgraded shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) from a neutral rating to an outperform rating in a research note issued to investors on Tuesday. The firm currently has $10.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $7.00.

Several other research firms have also commented on FOLD. Zacks Investment Research lowered Amicus Therapeutics from a hold rating to a sell rating in a report on Wednesday, November 23rd. Chardan Capital reaffirmed a buy rating and set a $16.00 target price (up from $15.00) on shares of Amicus Therapeutics in a report on Tuesday, November 29th. Cowen and Company reaffirmed an outperform rating and set a $15.00 target price on shares of Amicus Therapeutics in a report on Tuesday, November 8th. Leerink Swann reaffirmed a buy rating and set a $17.00 target price on shares of Amicus Therapeutics in a report on Tuesday, November 8th. Finally, J P Morgan Chase & Co reaffirmed an overweight rating and set a $11.00 target price (down from $12.00) on shares of Amicus Therapeutics in a report on Wednesday, November 30th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. Amicus Therapeutics presently has a consensus rating of Buy and a consensus target price of $11.42.

Shares of Amicus Therapeutics (NASDAQ:FOLD) traded down 0.468% on Tuesday, reaching $5.315. 1,108,872 shares of the company’s stock traded hands. The company has a 50 day moving average price of $5.38 and a 200 day moving average price of $6.73. Amicus Therapeutics has a 52 week low of $4.41 and a 52 week high of $9.83. The firm’s market capitalization is $756.46 million.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.01. The company had revenue of $2.10 million for the quarter, compared to analyst estimates of $1.71 million. On average, equities research analysts predict that Amicus Therapeutics will post ($1.40) earnings per share for the current fiscal year.

In other Amicus Therapeutics news, SVP Daphne Quimi sold 8,546 shares of the firm’s stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $8.00, for a total value of $68,368.00. Following the sale, the senior vice president now directly owns 24,189 shares of the company’s stock, valued at $193,512. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Perceptive Advisors Llc acquired 189,500 shares of the company’s stock in a transaction on Thursday, December 22nd. The stock was acquired at an average cost of $4.51 per share, for a total transaction of $854,645.00. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 511,650 shares of company stock worth $2,426,927 and sold 58,546 shares worth $393,368. 3.40% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of FOLD. DIAM Co. Ltd. raised its stake in shares of Amicus Therapeutics by 0.9% in the third quarter. DIAM Co. Ltd. now owns 565,245 shares of the biopharmaceutical company’s stock worth $3,996,000 after buying an additional 4,971 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in shares of Amicus Therapeutics during the third quarter worth about $29,750,000. Emerald Mutual Fund Advisers Trust raised its stake in shares of Amicus Therapeutics by 15.0% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 1,270,437 shares of the biopharmaceutical company’s stock worth $9,401,000 after buying an additional 165,610 shares in the last quarter. Candriam Luxembourg S.C.A. raised its stake in shares of Amicus Therapeutics by 14.5% in the second quarter. Candriam Luxembourg S.C.A. now owns 709,900 shares of the biopharmaceutical company’s stock worth $3,876,000 after buying an additional 90,000 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System raised its stake in shares of Amicus Therapeutics by 36.6% in the second quarter. State Board of Administration of Florida Retirement System now owns 55,248 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 14,810 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Related posts

Leave a Comment